Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient.
Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG. Löffler MW, et al. J Hepatol. 2016 Oct;65(4):849-855. doi: 10.1016/j.jhep.2016.06.027. Epub 2016 Jul 7. J Hepatol. 2016. PMID: 27397612 Free PMC article.
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bödder J, Schertel JM, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanović S, Löffler MW. Rammensee HG, et al. Among authors: loffler mw. J Immunother Cancer. 2019 Nov 15;7(1):307. doi: 10.1186/s40425-019-0796-5. J Immunother Cancer. 2019. PMID: 31730025 Free PMC article.
A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer.
Löffler MW, Nussbaum B, Jäger G, Jurmeister PS, Budczies J, Pereira PL, Clasen S, Kowalewski DJ, Mühlenbruch L, Königsrainer I, Beckert S, Ladurner R, Wagner S, Bullinger F, Gross TH, Schroeder C, Sipos B, Königsrainer A, Stevanović S, Denkert C, Rammensee HG, Gouttefangeas C, Haen SP. Löffler MW, et al. Front Immunol. 2019 Nov 19;10:2526. doi: 10.3389/fimmu.2019.02526. eCollection 2019. Front Immunol. 2019. PMID: 31803175 Free PMC article. Clinical Trial.
Pitfalls in the characterization of circulating and tissue-resident human γδ T cells.
Beucke N, Wesch D, Oberg HH, Peters C, Bochem J, Weide B, Garbe C, Pawelec G, Sebens S, Röcken C, Hashimoto H, Löffler MW, Nocerino P, Kordasti S, Kabelitz D, Schilbach K, Wistuba-Hamprecht K. Beucke N, et al. Among authors: loffler mw. J Leukoc Biol. 2020 Jun;107(6):1097-1105. doi: 10.1002/JLB.5MA1219-296R. Epub 2020 Jan 22. J Leukoc Biol. 2020. PMID: 31967358
[Tumor vaccines-therapeutic vaccination against cancer].
Rammensee HG, Löffler MW, Walz JS, Bokemeyer C, Haen SP, Gouttefangeas C. Rammensee HG, et al. Among authors: loffler mw. Internist (Berl). 2020 Jul;61(7):690-698. doi: 10.1007/s00108-020-00814-z. Internist (Berl). 2020. PMID: 32462251 Review. German.
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.
Rammensee HG, Gouttefangeas C, Heidu S, Klein R, Preuß B, Walz JS, Nelde A, Haen SP, Reth M, Yang J, Tabatabai G, Bösmüller H, Hoffmann H, Schindler M, Planz O, Wiesmüller KH, Löffler MW. Rammensee HG, et al. Among authors: loffler mw. Vaccines (Basel). 2021 Apr 24;9(5):428. doi: 10.3390/vaccines9050428. Vaccines (Basel). 2021. PMID: 33923363 Free PMC article.
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J, Zelba H, Spreuer J, Amaral T, Wagner NB, Gaissler A, Pop OT, Thiel K, Yurttas C, Soffel D, Forchhammer S, Sinnberg T, Niessner H, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler TK, Löffler MW, Weide B, Wistuba-Hamprecht K. Bochem J, et al. Among authors: loffler mw. J Immunother Cancer. 2021 Dec;9(12):e003439. doi: 10.1136/jitc-2021-003439. J Immunother Cancer. 2021. PMID: 34933966 Free PMC article.
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L. Löffler MW, et al. Clin Cancer Res. 2022 Jun 13;28(12):2555-2566. doi: 10.1158/1078-0432.CCR-21-4424. Clin Cancer Res. 2022. PMID: 35421231 Clinical Trial.
187 results